SCHEMBL20127170

SCHEMBL20127170

c1ccc(-c2nc(-c3ccccc3)nc(-c3ccc(C4(c5ccccc5)c5ccccc5-c5c4ccc4ccccc54)cc3)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 3/20 0.40
LMNA P02545 2/20 0.40
OPRK1 P41145 1/20 0.40
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
ATM Q13315 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
TSHR P16473 2/20 0.37
TP53 P04637 1/20 0.37
NFKB1 P19838 1/20 0.37
MAPK1 P28482 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21394016 0.99 MAPT (0.39) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL21394116 0.99 MAPT (0.39) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL21394113 0.99 MAPT (0.39) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL20127193 0.99 MAPT (0.39) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL21394241 0.99 MAPT (0.39) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL20127194 0.99 MAPT (0.39) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL21394019 0.99 MAPT (0.39) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL20127195 0.95 MAPT (0.39) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL20127181 0.95 MAPT (0.36) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL18818836 0.95 MAPT (0.36) MAPTMEN1KMT2ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220093873-A1 ORGANIC LIGHT EMITTING DEVICE LG CHEM, LTD. (KR) 2022-03-24 US disclosed
US-11239425-B2 Organic light emitting device LG CHEM, LTD. (KR) 2022-02-01 US disclosed
US-20210320255-A1 METHOD OF SCREENING FOR ELECTRON TRANSPORT MATERIAL AND HOLE BLOCKING MATERIAL USED IN ORGANIC LIGHT EMITTING DEVICE LG CHEM, LTD. (KR) 2021-10-14 US disclosed
US-20210280794-A1 NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME LG CHEM, LTD. (KR) 2021-09-09 US disclosed
US-10745362-B2 Heterocyclic compound and organic light emitting device comprising same LG CHEM, LTD. (KR) 2020-08-18 US disclosed
US-20190296243-A1 ORGANIC LIGHT EMITTING DEVICE LG CHEM, LTD. (KR) 2019-09-26 US disclosed
US-20180127385-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM LTD. (KR) 2018-05-10 US disclosed
US-20180127385-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM LTD. (KR) 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210280794-A1 NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME CRY1, CRY2, AOX1 MAPT 763/4885MEN1 956/4885KMT2A 2434/4885
US-10745362-B2 Heterocyclic compound and organic light emitting device comprising same CRY1, CRY2, PER2 MAPT 1073/4885MEN1 847/4885KMT2A 714/4885
US-20180127385-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME CRY1, CRY2, PER2 MAPT 1073/4885MEN1 847/4885KMT2A 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.